Literature DB >> 10735497

The value of rapid functional assays of germline p53 status in LFS and LFL families.

R S Camplejohn1, N Sodha, R Gilchrist, M E Lomax, P M Duddy, C Miner, P Alarcon-Gonzalez, D M Barnes, R A Eeles.   

Abstract

We have tested two rapid assays of p53 function, namely the apoptotic assay and the FASAY as means of detecting germline p53 mutations in members of Li-Fraumeni and Li-Fraumeni-like families. Results of the functional assays have been compared with direct sequencing of all 11 exons of the p53 gene. The results show good agreement between the two functional assays and between them and sequencing. No false-positives or negatives were seen with either functional assay although the apoptotic assay gave one borderline result for an individual without a mutation. As an initial screen the apoptotic assay is not only rapid but inexpensive and very simple to perform. It would be expected to detect any germline defect that leads to loss of p53 function. The apoptotic assay could be ideal as a means of prescreening large numbers of samples and identifying those that require further investigation. The FASAY detects mutations in exons 4-10, is rapid and distinguishes between functionally important and silent mutations.

Entities:  

Mesh:

Year:  2000        PMID: 10735497      PMCID: PMC2363355          DOI: 10.1054/bjoc.1999.1054

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.

Authors:  G Casey; M E Lopez; J C Ramos; S J Plummer; M J Arboleda; M Shaughnessy; B Karlan; D J Slamon
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

2.  Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.

Authors:  M E Lomax; D M Barnes; R Gilchrist; S M Picksley; J M Varley; R S Camplejohn
Journal:  Oncogene       Date:  1997-04-17       Impact factor: 9.867

3.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Authors:  F P Li; J F Fraumeni
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

Review 4.  Germline mutations in the TP53 gene.

Authors:  R A Eeles
Journal:  Cancer Surv       Date:  1995

5.  Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.

Authors:  J M Varley; G McGown; M Thorncroft; M F Santibanez-Koref; A M Kelsey; K J Tricker; D G Evans; J M Birch
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

6.  Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.

Authors:  J M Varley; P Chapman; G McGown; M Thorncroft; G R White; M J Greaves; D Scott; A Spreadborough; K J Tricker; J M Birch; D G Evans; R Reddel; R S Camplejohn; J Burn; J M Boyle
Journal:  Oncogene       Date:  1998-06-25       Impact factor: 9.867

7.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

8.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

9.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

Authors:  J M Birch; A L Hartley; K J Tricker; J Prosser; A Condie; A M Kelsey; M Harris; P H Jones; A Binchy; D Crowther
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

10.  A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage.

Authors:  R S Camplejohn; P Perry; S V Hodgson; G Turner; A Williams; C Upton; C MacGeoch; S Mohammed; D M Barnes
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  10 in total
  6 in total

1.  Detection of functional single-nucleotide polymorphisms that affect apoptosis.

Authors:  Sandra L Harris; German Gil; Harlan Robins; Wenwei Hu; Kim Hirshfield; Elisabeth Bond; Gareth Bond; Arnold J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

Review 2.  p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.

Authors:  R S Camplejohn; J Rutherford
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

3.  A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.

Authors:  Yann Neuzillet; Xavier Paoletti; Slah Ouerhani; Pierre Mongiat-Artus; Hany Soliman; Hugues de The; Mathilde Sibony; Yves Denoux; Vincent Molinie; Aurélie Herault; May-Linda Lepage; Pascale Maille; Audrey Renou; Dimitri Vordos; Claude-Clément Abbou; Ashraf Bakkar; Bernard Asselain; Nadia Kourda; Amel El Gaaied; Karen Leroy; Agnès Laplanche; Simone Benhamou; Thierry Lebret; Yves Allory; François Radvanyi
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

4.  Heritability of DNA-damage-induced apoptosis and its relationship with age in lymphocytes from female twins.

Authors:  R S Camplejohn; S Hodgson; N Carter; B S Kato; T D Spector
Journal:  Br J Cancer       Date:  2006-07-04       Impact factor: 7.640

5.  Investigations on a clinically and functionally unusual and novel germline p53 mutation.

Authors:  J Rutherford; C E Chu; P M Duddy; R S Charlton; P Chumas; G R Taylor; X Lu; D M Barnes; R S Camplejohn
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

6.  Apoptosis, ageing and cancer susceptibility.

Authors:  R S Camplejohn; R Gilchrist; D Easton; E McKenzie-Edwards; D M Barnes; D M Eccles; A Ardern-Jones; S V Hodgson; P M Duddy; R A Eeles
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.